BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9514426)

  • 1. Fecal calprotectin concentration in patients with colorectal carcinoma.
    Kristinsson J; Røseth A; Fagerhol MK; Aadland E; Schjønsby H; Børmer OP; Raknerud N; Nygaard K
    Dis Colon Rectum; 1998 Mar; 41(3):316-21. PubMed ID: 9514426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fecal excretion of calprotectin in colorectal cancer: relationship to tumor characteristics.
    Kristinsson J; Armbruster CH; Ugstad M; Kriwanek S; Nygaard K; Tøn H; Fuglerud P
    Scand J Gastroenterol; 2001 Feb; 36(2):202-7. PubMed ID: 11252414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma.
    Tibble J; Sigthorsson G; Foster R; Sherwood R; Fagerhol M; Bjarnason I
    Gut; 2001 Sep; 49(3):402-8. PubMed ID: 11511563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and histopathological correlations of fecal calprotectin release in colorectal carcinoma.
    Lehmann FS; Trapani F; Fueglistaler I; Terracciano LM; von Flüe M; Cathomas G; Zettl A; Benkert P; Oertli D; Beglinger C
    World J Gastroenterol; 2014 May; 20(17):4994-9. PubMed ID: 24803811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy.
    Limburg PJ; Ahlquist DA; Sandborn WJ; Mahoney DW; Devens ME; Harrington JJ; Zinsmeister AR
    Am J Gastroenterol; 2000 Oct; 95(10):2831-7. PubMed ID: 11051356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Faecal calprotectin: a novel test for the diagnosis of colorectal cancer?
    Røseth AG; Kristinsson J; Fagerhol MK; Schjønsby H; Aadland E; Nygaard K; Roald B
    Scand J Gastroenterol; 1993 Dec; 28(12):1073-6. PubMed ID: 8303210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new fecal calprotectin test for colorectal neoplasia. Clinical results and comparison with previous method.
    Johne B; Kronborg O; Tøn HI; Kristinsson J; Fuglerud P
    Scand J Gastroenterol; 2001 Mar; 36(3):291-6. PubMed ID: 11305517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fecal marker variability in colorectal cancer: calprotectin versus hemoglobin.
    Gilbert JA; Ahlquist DA; Mahoney DW; Zinsmeister AR; Rubin J; Ellefson RD
    Scand J Gastroenterol; 1996 Oct; 31(10):1001-5. PubMed ID: 8898421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic value of fecal calprotectin as a screening biomarker for gastrointestinal malignancies.
    Khoshbaten M; Pishahang P; Nouri M; Lashkari A; Alizadeh M; Rostami-Nejad M
    Asian Pac J Cancer Prev; 2014; 15(4):1667-70. PubMed ID: 24641386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening of first degree relatives of patients operated for colorectal cancer: evaluation of fecal calprotectin vs. hemoccult II.
    Kristinsson J; Nygaard K; Aadland E; Barstad S; Sauar J; Hofstad B; Stray N; Stallemo A; Haug B; Ugstad M; Tøn H; Fuglerud P
    Digestion; 2001; 64(2):104-10. PubMed ID: 11684824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm.
    Husebye E; Tøn H; Johne B
    Am J Gastroenterol; 2001 Sep; 96(9):2683-7. PubMed ID: 11569695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved assay for fecal calprotectin.
    Tøn H; Brandsnes ; Dale S; Holtlund J; Skuibina E; Schjønsby H; Johne B
    Clin Chim Acta; 2000 Feb; 292(1-2):41-54. PubMed ID: 10686275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia.
    Limburg PJ; Devens ME; Harrington JJ; Diehl NN; Mahoney DW; Ahlquist DA
    Am J Gastroenterol; 2003 Oct; 98(10):2299-305. PubMed ID: 14572583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is fecal calprotectin the next standard in inflammatory bowel disease activity tests?
    Alic M
    Am J Gastroenterol; 1999 Nov; 94(11):3370-1. PubMed ID: 10566749
    [No Abstract]   [Full Text] [Related]  

  • 15. [Fecal calprotectin in differential diagnosis of irritable bowel syndrome].
    Li XG; Lu YM; Gu F; Yang XL
    Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Jun; 38(3):310-3. PubMed ID: 16778979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of ileal pouch inflammation by single-stool calprotectin assay.
    Thomas P; Rihani H; Røseth A; Sigthorsson G; Price A; Nicholls RJ; Bjarnason I
    Dis Colon Rectum; 2000 Feb; 43(2):214-20. PubMed ID: 10696896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Faecal calprotectin levels and colorectal neoplasia.
    Brydon WG; Campbell SS; Anderson NA; Wilson RG; Ghosh S
    Gut; 2001 Apr; 48(4):579-80. PubMed ID: 11288736
    [No Abstract]   [Full Text] [Related]  

  • 18. Faecal calprotectin levels in a high risk population for colorectal neoplasia.
    Kronborg O; Ugstad M; Fuglerud P; Johne B; Hardcastle J; Scholefield JH; Vellacott K; Moshakis V; Reynolds JR
    Gut; 2000 Jun; 46(6):795-800. PubMed ID: 10807890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of fecal calprotectin as a biomarker in gastrointestinal disease.
    Burri E; Beglinger C
    Expert Rev Gastroenterol Hepatol; 2014 Feb; 8(2):197-210. PubMed ID: 24345070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between disease duration and usefulness of fecal calprotectin measurement in patients with Crohn's disease.
    Eder P; Stawczyk-Eder K; Łykowska-Szuber L; Krela-Kaźmierczak I; Klimczak K; Szymczak A; Szachta P; Linke K
    Pol Arch Med Wewn; 2014; 124(1-2):51-7. PubMed ID: 24424551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.